Debt-to-equity in % of Vor Biopharma Inc. from Q3 2021 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Vor Biopharma Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2025.
  • Vor Biopharma Inc. Debt-to-equity for the quarter ending September 30, 2025 was -118 %, a 394% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

Vor Biopharma Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -118 -158 -394% Sep 30, 2025
Q2 2025 -145 -179 -533% Jun 30, 2025
Q1 2025 52.7 +24.2 +84.9% Mar 31, 2025
Q4 2024 45.2 +20.3 +81.5% Dec 31, 2024
Q3 2024 40 +17.8 +80.3% Sep 30, 2024
Q2 2024 33.5 +11 +48.6% Jun 30, 2024
Q1 2024 28.5 +4.77 +20.1% Mar 31, 2024
Q4 2023 24.9 +1.06 +4.44% Dec 31, 2023
Q3 2023 22.2 +0.24 +1.09% Sep 30, 2023
Q2 2023 22.5 +5.26 +30.4% Jun 30, 2023
Q1 2023 23.7 +10.7 +81.5% Mar 31, 2023
Q4 2022 23.9 +13.2 +124% Dec 31, 2022
Q3 2022 22 +6.89 +45.7% Sep 30, 2022
Q2 2022 17.3 Jun 30, 2022
Q1 2022 13.1 Mar 31, 2022
Q4 2021 10.6 Dec 31, 2021
Q3 2021 15.1 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.